Article
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
Bullish
65.4
−100 Bearish
0
+100 Bullish
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
finance.yahoo.com
Published
Jul 15, 2026 · 3:34 pm
Article ID
654Z24O
Original URL
Open source
Sentiment Signal
Bullish
65.4
−100Neutral+100
More Like This